Erectile dysfunction is fundamentally a vascular condition — and regenerative medicine is investigating how to restore the blood vessel function that makes erections possible.
The Problem
A Common Condition, Rarely Discussed
Erectile dysfunction is one of the most prevalent health conditions affecting men over 40, yet it remains one of the least discussed. Studies estimate that ED affects:
- Approximately 52% of men aged 40-70 experience some degree of ED
- Prevalence increases with age — from mild forms in younger men to more severe forms in older age groups
- Complete ED triples from approximately 5% at age 40 to 15% at age 70<sup>1</sup>
The impact extends far beyond the bedroom. ED is strongly associated with reduced quality of life, relationship strain, depression, and loss of self-confidence. Perhaps most critically, ED is now recognised as an early warning sign of systemic cardiovascular disease — often appearing 3-5 years before a cardiac event<sup>2</sup>.
Yet the typical medical response has been pharmacological management: PDE5 inhibitors (sildenafil, tadalafil) that temporarily enhance blood flow but do nothing to address the underlying vascular deterioration. For 30-40% of men, these medications are ineffective or produce intolerable side effects.
Why Current Treatments Fall Short
None of these options restore the vascular and tissue function that enables natural erections. Regenerative medicine research is investigating whether this restoration is possible.
Understanding ED: The Vascular Science
How Erections Work — The Physiology
An erection is a precisely coordinated vascular event:
- Neural signalling: Sexual stimulation triggers parasympathetic nerve impulses to the penile vasculature
- Nitric oxide release: Endothelial cells lining cavernosal arteries release nitric oxide (NO)
- Smooth muscle relaxation: NO activates cyclic GMP, causing cavernosal smooth muscle to relax
- Arterial dilation: Cavernosal arteries dilate, increasing blood inflow by 20-40x
- Veno-occlusion: Expanding sinusoidal spaces compress subtunical venules against the tunica albuginea, trapping blood
- Rigidity: Intracavernosal pressure reaches 100+ mmHg, producing full rigidity
What Goes Wrong
ED occurs when any part of this cascade is disrupted. The primary mechanisms:
Endothelial dysfunction (most common — 70-80% of non-psychogenic ED):
- Damaged endothelial cells produce less nitric oxide
- Caused by atherosclerosis, diabetes, hypertension, smoking, metabolic syndrome
- The same process that causes coronary artery disease — penile arteries are simply smaller and show symptoms first<sup>2</sup>
Cavernosal smooth muscle atrophy:
- Chronic hypoxia from reduced blood flow leads to smooth muscle cell death
- Replaced by collagen (fibrosis) — tissue becomes less expandable
- Creates a vicious cycle: less blood flow → more smooth muscle loss → worse blood flow
Neuropathy:
- Diabetes, prostate surgery, spinal cord injury can damage penile nerves
- Without nerve signalling, the vascular cascade never initiates
Hormonal factors:
- Low testosterone reduces libido and contributes to smooth muscle atrophy
- Hormonal treatment alone rarely resolves established ED if vascular damage is present
The Regenerative Target
Regenerative therapies for ED focus on two primary goals:
- Restore endothelial function — repair or replace damaged endothelial cells to restore nitric oxide production
- Regenerate cavernosal tissue — replace fibrotic tissue with functional smooth muscle and healthy sinusoidal architecture
What the Research Says
Low-Intensity Shockwave Therapy (Li-ESWT) — Strongest Evidence
Li-ESWT applies focused acoustic energy to penile tissue, stimulating neovascularisation (new blood vessel formation) and endogenous stem cell recruitment.
Systematic Review and Meta-Analysis — Lu et al. (2017):
A comprehensive meta-analysis of 14 studies including 7 RCTs (833 patients total) evaluated Li-ESWT for ED<sup>3</sup>:
- Statistically significant improvement in IIEF-EF scores compared to sham treatment (mean difference: 2.00 points; 95% CI: 0.99-3.00; p < 0.001)
- Treatment responder rate: approximately 60-70% of patients showed clinically meaningful improvement
- Effects sustained at 6-12 months post-treatment in most studies
- Protocol: Typically 6-12 sessions over 6-9 weeks; 3,000-5,000 shockwaves per session
- Safety: No serious adverse events reported; mild temporary discomfort during treatment
Vardi et al. (2012) — The Landmark RCT:
The first rigorous double-blind, sham-controlled RCT enrolled 67 men with vasculogenic ED<sup>6</sup>:
- IIEF-EF increase of 6.7 points in treatment group vs. 3.0 in sham (p = 0.004)
- PDE5 inhibitor responders: Some patients who had failed sildenafil regained responsiveness
- Penile haemodynamics improved: Increased peak systolic velocity on penile Doppler ultrasound
- 12-month durability: Improvements maintained at 12-month follow-up
Platelet-Rich Plasma (PRP) — Promising Phase II Data
PRP injection for ED (sometimes called the "P-Shot") delivers concentrated growth factors directly to cavernosal tissue.
Epifanova et al. (2020) — Systematic Review:
A comprehensive review of clinical evidence for PRP therapy in male sexual dysfunction<sup>4</sup>:
- Reviewed multiple studies demonstrating PRP safety and potential efficacy for ED
- Mechanism: PRP growth factors (PDGF, VEGF, FGF) promote neovascularisation and smooth muscle regeneration in cavernosal tissue
- Conclusion: PRP shows promise but larger, well-designed RCTs are needed before clinical recommendations can be made
- Safety: No serious adverse events reported across reviewed studies
Poulios et al. (2021) — Double-Blind Randomised Controlled Trial:
A double-blind RCT comparing PRP injection to saline placebo in 60 men with ED<sup>7</sup>:
- IIEF-EF improvement at 6 months: baseline-adjusted mean between-group difference of 3.9 points (95% CI 1.8-5.9)
- 69% of PRP patients achieved clinically meaningful improvement vs. 27% of controls (p < 0.001)
- Statistically significant improvement at 1, 3, and 6 months
- No adverse events reported in either group
Mesenchymal Stem Cell Therapy — Investigational
Haahr et al. (2016) — Phase I Trial (Post-Prostatectomy ED):
A Phase I trial of autologous adipose-derived stem cells (ADSCs) in 17 men with ED following radical prostatectomy<sup>5</sup>:
- Safety confirmed: No serious adverse events at 12 months
- 8 of 17 patients (47%) regained erectile function sufficient for intercourse
- IIEF-5 improved by ≥5 points in responders
- Mechanism: ADSCs hypothesised to promote cavernous nerve regeneration and smooth muscle restoration
Yiou et al. (2016) — Dose-Escalation Phase I:
A dose-escalation study of bone marrow-derived mononuclear cells in 12 men with post-prostatectomy ED<sup>8</sup>:
- Dose-dependent improvement: Higher doses showed greater IIEF-EF improvement
- Morning erections returned in several patients — suggesting restoration of physiological erectile function
- MRI evidence: Improved cavernosal enhancement on dynamic contrast MRI, suggesting neovascularisation
Summary of Evidence
Treatment Approach at Our Clinic
Evidence-Based Protocol
Our approach focuses on the treatments with the strongest clinical evidence, presented honestly:
Candidacy
Ideal candidates:
- Men aged 40-75 with vasculogenic ED (the most common type)
- Those who respond partially to PDE5 inhibitors and want to improve natural function
- Men who prefer to address root causes rather than manage symptoms
- Post-prostatectomy patients (for nerve recovery protocols)
- Those with diabetes-related ED (vascular component)
Important considerations:
- Severe Peyronie's disease may require additional evaluation
- Purely psychogenic ED may benefit more from psychological intervention
- Active urinary tract infection must be resolved before treatment
- Uncontrolled cardiovascular disease should be stabilised first
What to Expect: Our Men's Vascular Health Programme
Phase 1: Comprehensive Assessment (Day 1-2)
- Confidential medical history and sexual health assessment
- Penile Doppler ultrasonography — objective measure of vascular function
- Cardiovascular screening — ED is a vascular condition, and your heart health matters
- Blood panel: testosterone, metabolic markers, inflammatory markers
Phase 2: Treatment (Day 3-5)
- Li-ESWT sessions (protocol based on individual assessment)
- PRP preparation and cavernosal injection (if indicated)
- IV NAD+ and vascular support therapy
- Pelvic floor physiotherapy education
Phase 3: Optimisation & Follow-Up (Day 6-7)
- Hormonal management plan if indicated
- Cardiovascular risk factor management (nutrition, exercise, supplements)
- Home pelvic floor exercise programme
- Follow-up schedule: 1-month, 3-month, and 6-month assessments
- Repeat treatment planning if needed
Results Timeline
Frequently Asked Questions
Q: Why is ED considered a vascular condition?
A: The penile arteries (1-2mm diameter) are among the smallest in the body. The same endothelial dysfunction and atherosclerosis that eventually cause heart attacks and strokes affect these arteries first, because smaller vessels are more sensitive to damage. This is why ED often appears 3-5 years before cardiovascular events<sup>2</sup>. Treating ED at the vascular level isn't just about sexual function — it's about addressing systemic vascular health.
Q: Will I still need Viagra/Cialis after treatment?
A: The goal of regenerative treatment is to reduce or eliminate dependence on medication. In clinical trials, approximately 60-70% of Li-ESWT patients showed meaningful improvement, with some patients who had failed PDE5 inhibitors regaining responsiveness. However, results vary — some patients may continue to benefit from occasional medication use even after treatment.
Q: Is the PRP injection painful?
A: A topical anaesthetic (lidocaine cream) and/or penile nerve block is applied before the procedure. Most patients report mild pressure rather than pain during the injection. Post-procedure discomfort is typically minimal (mild soreness for 24-48 hours) and does not require prescription pain management.
Q: How is this different from the treatments I see advertised online?
A: The landscape for men's sexual health treatments includes many unregulated or poorly evidenced offerings. What differentiates the Sterling-certified approach: only treatments with published clinical trial data (Li-ESWT, PRP) are used, comprehensive vascular diagnostics are performed before treatment, and full transparency is maintained about what the evidence does and does not support. No claims are made that exceed the published research.
Q: I'm diabetic — does this approach work for diabetes-related ED?
A: Diabetes-related ED involves both vascular and neurological components. Li-ESWT has shown efficacy in diabetic ED populations, though response rates may be somewhat lower than in non-diabetic vasculogenic ED. PRP and stem cell research specifically includes diabetic populations. A thorough assessment of your vascular and metabolic status helps set realistic expectations.
Take the Next Step
Ready to address the root cause of erectile dysfunction?
- Take our 2-minute Health Assessment to tell us about your situation — completely confidential
- Book a Discovery Consultation to discuss vascular health treatment options
Every conversation is confidential, medically professional, and focused on your health.